THE OUTCOMES OF NEOADJUVANT CHEMOTHERAPY IN STAGE IIIC-IV EPITHELIAL OVARIAN CANCER PATIENTS AT THAI NGUYEN NATIONAL HOSPITAL
Main Article Content
Abstract
Objective: Evaluate the treatment outcomes of neoadjuvant chemotherapy in patients with stage IIIC-IV ovarian carcinoma at Thai Nguyen Central Hospital.
Research subjects and methods: A retrospective-prospective descriptive study was conducted on 36 patients with stage IIIC-IV ovarian carcinoma who received neoadjuvant chemotherapy at the Oncology Center, Thai Nguyen National Hospital, between January, 2019, and December, 2025.
Research results: The mean age was 58.61 ± 9.34 years; 86.1% had an Eastern Cooperative Oncology Group performance status of 0-1. Stage IIIC and stage IV disease accounted for 52.8% and 47.2% of cases, respectively. The Paclitaxel-Carboplatin regimen was the most commonly used (66.7%). The objective response rate was 88.9%. However, only 28 patients underwent optimal debulking surgery following neoadjuvant chemotherapy; results showed a partial response in 69.5% of patients and a complete pathological response in 8.3%, with an optimal surgery rate of 75,0%. Grade 3-4 adverse events were predominantly hematological ones.
Conclusion: Neoadjuvant chemotherapy provided effective outcomes, increased the rate of optimal cytoreductive surgery, and had an acceptable safety profile in patients with stage IIIC-IV ovarian carcinoma.
Keywords
Epithelial ovarian cancer, advanced stage, neoadjuvant chemotherapy, treatment response, toxicity
Article Details
References
2. Vũ Hải Hằng, et al. Hiệu quả của phác đồ Carboplatin/Paclitaxel có hoặc không có Bevacizumab trong ung thư biểu mô buồng trứng giai đoạn tiến xa. Tạp chí Y Dược Thực hành 175, 10, doi:10.59354/ydth175.2024.242 (2024).
3. Nguyễn Thị Phương Liên, et al. Kết quả điều trị và tác dụng không mong muốn hóa trị tân bổ trợ phác đồ Paclitaxel - Carboplatin trong ung thư biểu mô buồng trứng giai đoạn III, IV tại Bệnh viện tỉnh Phú Thọ. Tạp chí Y học Việt Nam 554, doi:10.51298/vmj.v554i3.15723 (2025).
4. Nguyễn Thị Thanh Loan, Lê Thanh Đức và Hàn Thị Thanh Bình. Đánh giá kết quả hóa trị tân bổ trợ phác đồ Paclitaxel - Carboplatin trong ung thư buồng trứng giai đoạn III-IV tại Bệnh viện K. Tạp chí Y học Việt Nam 530, doi:10.51298/vmj.v530i2.6822 (2023).
5. Lê Thị Yến và Nguyễn Thị Mai Lương. Kết quả bước đầu và các yếu tố liên quan hóa trị tân bổ trợ phác đồ Paclitaxel - Carboplatin ung thư biểu mô buồng trứng giai đoạn IIIC-IV tại Bệnh viện K. Tạp chí Y học Việt Nam 548, doi:10.51298/vmj.v548i2.13370 (2025).
6. Sung, H. et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA: a cancer journal for clinicians 76, e70090, doi:10.3322/caac.70090 (2026).
7. Vergote, I. et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. The Lancet Oncology 19, 1680-1687, doi:10.1016/S1470-2045(18)30566-7 (2018).
8. Ledermann, J. A. et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Annals of oncology : official journal of the European Society for Medical Oncology 35, 248-266, doi:10.1016/j.annonc.2023.11.015 (2024).
9. Onda, T. et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. European journal of cancer (Oxford, England : 1990) 64, 22-31, doi:10.1016/j.ejca.2016.05.017 (2016).